WO2005110360A3 - Compositions for injection - Google Patents

Compositions for injection Download PDF

Info

Publication number
WO2005110360A3
WO2005110360A3 PCT/EP2005/005365 EP2005005365W WO2005110360A3 WO 2005110360 A3 WO2005110360 A3 WO 2005110360A3 EP 2005005365 W EP2005005365 W EP 2005005365W WO 2005110360 A3 WO2005110360 A3 WO 2005110360A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
injection
composition
intramuscular
preparation
Prior art date
Application number
PCT/EP2005/005365
Other languages
French (fr)
Other versions
WO2005110360A2 (en
Inventor
Steve Leigh
Mathew Louis Steven Leigh
Hoogevest Peter Van
Original Assignee
Phares Pharm Res Nv
Steve Leigh
Mathew Louis Steven Leigh
Hoogevest Peter Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phares Pharm Res Nv, Steve Leigh, Mathew Louis Steven Leigh, Hoogevest Peter Van filed Critical Phares Pharm Res Nv
Publication of WO2005110360A2 publication Critical patent/WO2005110360A2/en
Publication of WO2005110360A3 publication Critical patent/WO2005110360A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases

Abstract

The present invention relates to a homogeneous pharmaceutical composition for the gradual release of biologically active compounds after intramuscular or subcutaneous administration comprising at least one membrane lipid which is in the liquid crystalline state and a process for the preparation of said composition.
PCT/EP2005/005365 2004-05-18 2005-05-17 Compositions for injection WO2005110360A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04252942.0 2004-05-18
EP04252942 2004-05-18

Publications (2)

Publication Number Publication Date
WO2005110360A2 WO2005110360A2 (en) 2005-11-24
WO2005110360A3 true WO2005110360A3 (en) 2006-04-06

Family

ID=35394648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005365 WO2005110360A2 (en) 2004-05-18 2005-05-17 Compositions for injection

Country Status (1)

Country Link
WO (1) WO2005110360A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101494594B1 (en) 2011-08-30 2015-02-23 주식회사 종근당 Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
KR101586790B1 (en) 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004611A (en) * 1984-03-08 1991-04-02 Phares Pharmaceutical Research Nv Pro-liposome compositions
EP0648494A1 (en) * 1993-09-30 1995-04-19 American Home Products Corporation Rapamycin formulations for oral administration
US6599527B1 (en) * 1997-06-20 2003-07-29 Phares Pharmaceutical Research N.V. Preparation of pharmaceutical compositions
US6605298B1 (en) * 1998-03-05 2003-08-12 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004611A (en) * 1984-03-08 1991-04-02 Phares Pharmaceutical Research Nv Pro-liposome compositions
EP0648494A1 (en) * 1993-09-30 1995-04-19 American Home Products Corporation Rapamycin formulations for oral administration
US6599527B1 (en) * 1997-06-20 2003-07-29 Phares Pharmaceutical Research N.V. Preparation of pharmaceutical compositions
US6605298B1 (en) * 1998-03-05 2003-08-12 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURTHA J L ET AL: "SYNTHESIS OF THE CHOLESTERYL ESTER PRODRUGS CHOLESTERYL IBUPROFEN AND CHOLESTERYL FLUFENAMATE AND THEIR FORMULATION INTO PHOSPHOLIPID MICROEMULSIONS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 83, no. 9, 1 September 1994 (1994-09-01), pages 1222 - 1228, XP000465804, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
WO2005110360A2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2008041245A3 (en) Injectable depot composition and it's process of preparation
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
WO2005112633A3 (en) Compounds and compositions for delivering active agents
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
EP2422798A3 (en) Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2010041141A3 (en) Oil-based foamable carriers and formulations
EA200700389A1 (en) STABLE FOR STORAGE INFUSION SOLUTION OF DIHYDROPTERIDINONES
WO2006065951A3 (en) Sustained delivery formulations of octreotide compounds
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
WO2008108286A1 (en) Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
UA96302C2 (en) Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid
WO2008113901A3 (en) Composition with controlled release of levetiracetam and method for preparing same
WO2008039415A3 (en) Analogs of ghrelin substituted at the n-terminal
WO2008107149A3 (en) Pharmaceutical form with impeded abuse
WO2007047948A3 (en) Intranasal administration of rapid acting insulin
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2009061607A3 (en) Water-immiscible materials as vehicles for drug delivery
WO2008035020A3 (en) Galenic form for the trans-mucosal delivery of active ingredients
WO2008065097A3 (en) Stabilized solid pharmaceutical composition of candesartan cilexetil
WO2006079928A3 (en) Polyelectrolyte multilayer film, preparation and uses thereof
ATE413865T1 (en) COMPOSITIONS WITH ALPHAHYDROXY ACID ESTERS FOR THE RELEASE OF ACTIVE INGREDIENTS AND METHODS OF USE THEREOF
CL2007003346A1 (en) COMPOUNDS DERIVED FROM 2,5-DIHIDRO-3H-PIRAZOLO [4,3-C] PIRIDAZIN-3-ONA; PREPARATION PROCEDURE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS SYSTROME OF ABSTINENCE TO A SUBSTANCE, AFTER

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase